Home/Pipeline/LAM561 / Platform

LAM561 / Platform

Alzheimer's Disease

Preclinical/ResearchActive

Key Facts

Indication

Alzheimer's Disease

Phase

Preclinical/Research

Status

Active

Company

Laminar Pharmaceuticals

About Laminar Pharmaceuticals

Laminar Pharmaceuticals, founded in 2006 as a spin-off from the University of the Balearic Islands, is developing a novel class of drugs based on its proprietary Membrane Lipid Therapy (MELItherapy) platform. Its lead asset, LAM561 (idroxioleic acid/2-hydroxyoleic acid), is in a pivotal Phase 2b/3 trial (CLINGLIO) for newly diagnosed glioblastoma, with other programs targeting neurodegenerative and rare diseases. The company is privately held, pre-revenue, and is currently seeking a new capital round to advance its clinical pipeline.

View full company profile

Therapeutic Areas

Oncology Neurodegenerative Diseases Rare Diseases

Other Alzheimer's Disease Drugs

Drug	Company	Phase	Status
NUZ-001	Neurizon Therapeutics	Preclinical	Active
ALZN002	Alzamend Neuro	Preclinical	Research
P021	Phanes Biotech	Preclinical	Active
PB43D	Phanes Biotech	Preclinical	Active
UB-311	Vaxxinity	Phase 2	Active
Lecanemab	BioArctic	Launched	Active (Commercial)
BAN2401	BioArctic	Preclinical	Active
Undisclosed Programs	johnson-and-johnson-innovative-medicine	Pipeline	Active
MK-6240 (florquinitau)	Lantheus Medical Imaging	Regulatory Filing	Filed
NAV-4694 (flutafuranol)	Lantheus Medical Imaging	Phase 3	Active
LNTH-2620/PI-2620	Lantheus Medical Imaging	Phase 3	Recruiting
itMSCs	Stemedica Cell Technologies	Clinical Development	Active